{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T01:12:46Z","timestamp":1790039566282,"version":"4.0.1"},"publisher-location":"Chichester, UK","reference-count":102,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd007654.pub3","type":"reference-entry","created":{"date-parts":[[2013,3,29]],"date-time":"2013-03-29T21:26:47Z","timestamp":1364592407000},"source":"Crossref","is-referenced-by-count":14,"title":["Long-term effects of weight-reducing drugs in hypertensive patients"],"prefix":"10.1002","author":[{"given":"Andrea","family":"Siebenhofer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Jeitler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Horvath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Berghold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Siering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Semlitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,28]]},"reference":[{"issue":"11","key":"10.1002\/14651858.CD007654.pub3-BIB1|cit1","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1097\/00004872-200211000-00026","article-title":"Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension","volume":"20","author":"Bakris","year":"2002","journal-title":"Journal of Hypertension"},{"issue":"2","key":"10.1002\/14651858.CD007654.pub3-BIB2|cit2","first-page":"68","article-title":"Sufficient weight reduction decreases cardiovascular complications in diabetic patients with the metabolic syndrome: A randomized study of orlistat as an adjunct to lifestyle changes (diet and exercise)","volume":"5","author":"Cocco","year":"2005","journal-title":"HeartDrug"},{"issue":"2","key":"10.1002\/14651858.CD007654.pub3-BIB3|cit3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF02850257","article-title":"Safety and efficacy of sibutramine in overweight Hispanic patients with hypertension","volume":"20","author":"Fanghaenel","year":"2003","journal-title":"Advances in Therapy"},{"issue":"3","key":"10.1002\/14651858.CD007654.pub3-BIB4|cit4","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1463-1326.2005.00465.x","article-title":"Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients","volume":"7","author":"Faria","year":"2005","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD007654.pub3-BIB5|cit5","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1590\/S0066-782X2002000200006","article-title":"Effects of sibutramine on the treatment of obesity in patients with arterial hypertension. Portuguese, English]","volume":"78","author":"Faria","year":"2002","journal-title":"Arquivos Brasileiros de Cardiologia"},{"issue":"5","key":"10.1002\/14651858.CD007654.pub3-BIB6|cit6","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1462-8902.2004.00359.x","article-title":"Effects of orlistat on obesity-related diseases - a six-month randomized trial","volume":"6","author":"Guy-Grand","year":"2004","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"14","key":"10.1002\/14651858.CD007654.pub3-BIB7|cit7","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1001\/archinte.160.14.2185","article-title":"Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial","volume":"160","author":"McMahon","year":"2000","journal-title":"Archives of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD007654.pub3-BIB8|cit8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/sj.jhh.1001298","article-title":"Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors","volume":"16","author":"McMahon","year":"2002","journal-title":"Journal of Human Hypertension"},{"key":"10.1002\/14651858.CD007654.pub3-BIB9|cit9","first-page":"19","article-title":"Evaluation of the benefits and harms of non-drug weight-reducing treatment strategies in patients with essential hypertension","volume-title":"http:\/\/iqwig.de\/download\/A05-21A_Abschlussbericht_Gewichtsreduktion_bei_Bluthochdruck_neu.pdf","author":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen","year":"2006"},{"issue":"5","key":"10.1002\/14651858.CD007654.pub3-BIB10|cit10","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0197-2456(01)00165-9","article-title":"Principles for enhanced recruitment of subjects in a large clinical trial. the XENDOS (XENical in the prevention of Diabetes in Obese Subjects) study experience","volume":"22","author":"Torgerson","year":"2001","journal-title":"Controlled Clinical Trials"},{"issue":"1","key":"10.1002\/14651858.CD007654.pub3-BIB11|cit11","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/diacare.27.1.155","article-title":"XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients","volume":"27","author":"Torgerson","year":"2004","journal-title":"Diabetes care"},{"issue":"4","key":"10.1002\/14651858.CD007654.pub3-BIB12|cit12","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/j.1550-8528.1999.tb00419.x","article-title":"Absence of cardiac valve dysfunction in obese patients treated with sibutramine","volume":"7","author":"Bach","year":"1999","journal-title":"Obesity Research"},{"issue":"2","key":"10.1002\/14651858.CD007654.pub3-BIB13|cit13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/j.1550-8528.1999.tb00701.x","article-title":"Sibutramine produces dose-related weight loss","volume":"7","author":"Bray","year":"1999","journal-title":"Obesity Research"},{"issue":"7","key":"10.1002\/14651858.CD007654.pub3-BIB14|cit14","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1742-1241.2002.tb11307.x","article-title":"Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study","volume":"56","author":"Broom","year":"2002","journal-title":"International Journal of Clinical Practice"},{"issue":"3","key":"10.1002\/14651858.CD007654.pub3-BIB15|cit15","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jama.281.3.235","article-title":"Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.see comment]erratum appears in JAMA 1999 Apr 7;281(13):1174]","volume":"281","author":"Davidson","year":"1999","journal-title":"JAMA"},{"issue":"12","key":"10.1002\/14651858.CD007654.pub3-BIB16|cit16","first-page":"1361","article-title":"A randomized double-blind study comparing the efficacy and safety of orlistat versus placebo in obese patients with mild to moderate hypercholesterolemia","volume":"28","author":"Castro","year":"2009","journal-title":"Rev Port Cardiol"},{"issue":"4","key":"10.1002\/14651858.CD007654.pub3-BIB17|cit17","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0149-2918(03)80070-X","article-title":"Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet","volume":"25","author":"Derosa","year":"2003","journal-title":"Clinical Therapeutics"},{"issue":"11","key":"10.1002\/14651858.CD007654.pub3-BIB18|cit18","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.metabol.2008.06.010","article-title":"Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone","volume":"57","author":"Derosa","year":"2008","journal-title":"Metabolism: Clinical & Experimental"},{"issue":"3","key":"10.1002\/14651858.CD007654.pub3-BIB19|cit19","doi-asserted-by":"crossref","first-page":"378","DOI":"10.18433\/J3388P","article-title":"Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients","volume":"13","author":"Derosa","year":"2010","journal-title":"J Pharm Pharm Sci"},{"issue":"5","key":"10.1002\/14651858.CD007654.pub3-BIB20|cit20","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1365-2710.2010.01217.x","article-title":"Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients","volume":"36","author":"Derosa","year":"2011","journal-title":"J Clin Pharm Ther"},{"issue":"20","key":"10.1002\/14651858.CD007654.pub3-BIB21|cit21","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa044537","article-title":"Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia","volume":"353","author":"Despres","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD007654.pub3-BIB22|cit22","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1161\/ATVBAHA.108.176362","article-title":"Effect of rimonabant on the high-triglyceride\/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial","volume":"29","author":"Despres","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1002\/14651858.CD007654.pub3-BIB23|cit23","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1067\/mhj.2001.117510","article-title":"Effects of sibutramine on body weight and serum lipids: A double-blind, randomized, placebocontrolled study in 322 overweight and obese patients with dyslipidemia","volume":"142","author":"Dujovne","year":"2001","journal-title":"American heart journal"},{"issue":"11","key":"10.1002\/14651858.CD007654.pub3-BIB24|cit24","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/j.1365-2036.2004.01966.x","article-title":"Cholesterol lowering effect of dietary weight loss and orlistat treatment - Efficacy and limitations","volume":"19","author":"Erdmann","year":"2004","journal-title":"Alimentary Pharmacology and Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD007654.pub3-BIB25|cit25","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/sj.ijo.0801098","article-title":"A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity","volume":"24","author":"Fanghanel","year":"2000","journal-title":"International Journal of Obesity & Related Metabolic Disorders: Journal of the International Association for the Study of Obesity"},{"issue":"5","key":"10.1002\/14651858.CD007654.pub3-BIB26|cit26","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/sj.ijo.0801592","article-title":"Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over","volume":"25","author":"Fanghanel","year":"2001","journal-title":"International Journal of Obesity & Related Metabolic Disorders: Journal of the International Association for the Study of Obesity"},{"issue":"3","key":"10.1002\/14651858.CD007654.pub3-BIB27|cit27","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/sj.ijo.0801128","article-title":"One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor","volume":"24","author":"Finer","year":"2000","journal-title":"International Journal of Obesity & Related Metabolic Disorders: Journal of the International Association for the Study of Obesity"},{"issue":"3","key":"10.1002\/14651858.CD007654.pub3-BIB28|cit28","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1046\/j.1463-1326.2000.00081.x","article-title":"Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus","volume":"2","author":"Fujioka","year":"2000","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD007654.pub3-BIB29|cit29","first-page":"90","article-title":"Efficacy and safety of a short-time orlistat treatment in obese subjects]. Italian]","volume":"20","author":"Gentile","year":"2005","journal-title":"Annali Italiani di Medicina Interna"},{"issue":"7","key":"10.1002\/14651858.CD007654.pub3-BIB30|cit30","first-page":"24","article-title":"Add-on sibutramine for olanzapine-induced weight gain","volume":"11","author":"Ginsberg","year":"2004","journal-title":"Primary Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD007654.pub3-BIB31|cit31","first-page":"98","article-title":"Evaluation of efficacy, reliability, and tolerability of sibutramine in obese patients, with an echocardiographic study","volume":"57","author":"Halpern","year":"2002","journal-title":"Revista do Hospital das Clinicas; Faculdade de Medicina Da Universidade de Sao Paulo"},{"issue":"3","key":"10.1002\/14651858.CD007654.pub3-BIB32|cit32","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1046\/j.1463-1326.2003.00262.x","article-title":"Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients","volume":"5","author":"Halpern","year":"2003","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"4","key":"10.1002\/14651858.CD007654.pub3-BIB33|cit33","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1055\/s-2004-817934","article-title":"Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study","volume":"112","author":"Hauner","year":"2004","journal-title":"Experimental & Clinical Endocrinology & Diabetes"},{"issue":"2","key":"10.1002\/14651858.CD007654.pub3-BIB34|cit34","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1001\/archfami.9.2.160","article-title":"Orlistat in the long-term treatment of obesity in primary care settings.see comment]","volume":"9","author":"Hauptman","year":"2000","journal-title":"Archives of Family Medicine"},{"issue":"9","key":"10.1002\/14651858.CD007654.pub3-BIB35|cit35","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.numecd.2008.12.008","article-title":"Effect of diet-induced weight loss on plasma apelin and cytokine levels in individuals with the metabolic syndrome","volume":"19","author":"Heinonen","year":"2009","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD007654.pub3-BIB36|cit36","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.amjmed.2006.11.014","article-title":"Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus","volume":"120","author":"Hollander","year":"2007","journal-title":"American Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD007654.pub3-BIB37|cit37","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/j.1464-5491.2005.01569.x","article-title":"Sibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with Type 2 diabetes","volume":"22","author":"Hung","year":"2005","journal-title":"Diabetic Medicine"},{"issue":"2","key":"10.1002\/14651858.CD007654.pub3-BIB38|cit38","doi-asserted-by":"crossref","first-page":"99","DOI":"10.4103\/2230-8210.81938","article-title":"Evaluation of efficacy and safety of orlistat in obese patients","volume":"15","author":"Jain","year":"2011","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1002\/14651858.CD007654.pub3-BIB39|cit39","article-title":"A one-year trial to assess the value of orlistat in the management of obesity","volume":"21 Suppl 3:S24-","author":"James","year":"1997","journal-title":"International Journal of Obesity & Related Metabolic Disorders: Journal of the International Association for the Study of Obesity"},{"issue":"9248","key":"10.1002\/14651858.CD007654.pub3-BIB40|cit40","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0140-6736(00)03491-7","article-title":"Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance.see comment]","volume":"356","author":"James","year":"2000","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD007654.pub3-BIB41|cit41","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/sj.ijo.0802591","article-title":"Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes","volume":"28","author":"Kaukua","year":"2004","journal-title":"International Journal of Obesity & Related Metabolic Disorders: Journal of the International Association for the Study of Obesity"},{"issue":"6","key":"10.1002\/14651858.CD007654.pub3-BIB42|cit42","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2337\/diacare.25.6.1033","article-title":"Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial.erratum appears in Diabetes Care. 2003 Mar;26(3):971.]","volume":"25","author":"Kelley","year":"2002","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1002\/14651858.CD007654.pub3-BIB43|cit43","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1365-2796.2000.00720.x","article-title":"The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study.see comment]","volume":"248","author":"Lindgarde","year":"2000","journal-title":"Journal of Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD007654.pub3-BIB44|cit44","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1136\/ebm.6.2.54","article-title":"Orlistat with diet was effective and safe for weight loss and coronary risk reduction in obesity","volume":"6","author":"Lindgarde","year":"2001","journal-title":"Evidence-Based Medicine"},{"issue":"1","key":"10.1002\/14651858.CD007654.pub3-BIB45|cit45","first-page":"171","article-title":"Effect of orlistat on coronary heart disease risk in obese patients with hypertension and\/or hyperlipidemia","volume":"141","author":"Lindgarde","year":"2001","journal-title":"Am Heart J"},{"issue":"7","key":"10.1002\/14651858.CD007654.pub3-BIB46|cit46","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.metabol.2009.02.031","article-title":"Long-term weight loss decreases the nontraditional cardiovascular risk factors interleukin-18 and matrix metalloproteinase-9 in obese subjects","volume":"58","author":"Madsen","year":"2009","journal-title":"Metabolism"},{"issue":"1","key":"10.1002\/14651858.CD007654.pub3-BIB47|cit47","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2337\/diacare.26.1.125","article-title":"A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin","volume":"26","author":"McNulty","year":"2003","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1002\/14651858.CD007654.pub3-BIB48|cit48","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.2337\/diacare.25.7.1123","article-title":"Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin.erratum appears in Diabetes Care. 2002 Sep;25(9):1671.]","volume":"25","author":"Miles","year":"2002","journal-title":"Diabetes Care"},{"issue":"13","key":"10.1002\/14651858.CD007654.pub3-BIB49|cit49","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1001\/jama.299.13.1547","article-title":"Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial","volume":"299","author":"Nissen","year":"2008","journal-title":"JAMA"},{"issue":"14","key":"10.1002\/14651858.CD007654.pub3-BIB50|cit50","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/hrt.2011.223446","article-title":"Effect of rimonabant on carotid intima-media thickness (CIMT) progression in patients with abdominal obesity and metabolic syndrome: the AUDITOR Trial","volume":"97","author":"O'Leary","year":"2011","journal-title":"Heart"},{"issue":"1","key":"10.1002\/14651858.CD007654.pub3-BIB51|cit51","first-page":"1","article-title":"Orlistat as an adjunct therapy in type 2 obese diabetic patients treated with sulphonylurea: a Bangladesh experience","volume":"30","author":"Pathan","year":"2004","journal-title":"Bangladesh Medical Research Council Bulletin"},{"issue":"12","key":"10.1002\/14651858.CD007654.pub3-BIB52|cit52","first-page":"32","article-title":"Obesity-related hypertension","volume":"24","author":"Patschan","year":"2007","journal-title":"Cardiology Review"},{"issue":"7","key":"10.1002\/14651858.CD007654.pub3-BIB53|cit53","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.295.7.761","article-title":"Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.see comment]erratum appears in JAMA. 2006 Mar 15;295(11):1252]","volume":"295","author":"Pi-Sunyer","year":"2006","journal-title":"JAMA"},{"issue":"7","key":"10.1002\/14651858.CD007654.pub3-BIB54|cit54","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0002-9149(00)01521-6","article-title":"Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X","volume":"87","author":"Reaven","year":"2001","journal-title":"American Journal of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD007654.pub3-BIB55|cit55","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/oby.2000.8","article-title":"Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group","volume":"8","author":"Rossner","year":"2000","journal-title":"Obesity Research"},{"issue":"15","key":"10.1002\/14651858.CD007654.pub3-BIB56|cit56","first-page":"1802","article-title":"Sibutramine--antidepressive agent tested against obesity. [Swedish]","volume":"98","author":"Rossner","year":"2001","journal-title":"Lakartidningen"},{"issue":"3","key":"10.1002\/14651858.CD007654.pub3-BIB57|cit57","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1046\/j.1463-1326.2003.00264.x","article-title":"Decreasing levels of tumour necrosis factor alpha and interleukin 6 during lowering of body mass index with orlistat or placebo in obese subjects with cardiovascular risk factors","volume":"5","author":"Samuelsson","year":"2003","journal-title":"Diabetes, Obesity and Metabolism"},{"issue":"6 I","key":"10.1002\/14651858.CD007654.pub3-BIB58|cit58","first-page":"437","article-title":"New antiobesity agents in type 2 diabetes: Overview of clinical trials with sibutramine and orlistat","volume":"28","author":"Scheen","year":"2002","journal-title":"Diabetes and Metabolism"},{"issue":"var.pagings). 5","key":"10.1002\/14651858.CD007654.pub3-BIB59|cit59","doi-asserted-by":"crossref","first-page":"A141.E1326","DOI":"10.1016\/S0735-1097(10)61327-7","article-title":"Effects on mortality and morbidity in overweight\/obese subjects: The sibutramine cardiovascular outcomes (SCOUT) trial","volume":"Conference: Ame","author":"James","year":"2010","journal-title":"Journal of the American College of Cardiology"},{"issue":"10","key":"10.1002\/14651858.CD007654.pub3-BIB60|cit60","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMoa1003114","article-title":"Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects","volume":"363","author":"James","year":"2010","journal-title":"N Engl J Med"},{"issue":"suppl_L","key":"10.1002\/14651858.CD007654.pub3-BIB61|cit61","doi-asserted-by":"crossref","first-page":"L44","DOI":"10.1093\/eurheartj\/sui086","article-title":"The SCOUT study: risk-benefit profile of sibutramine in overweight high-risk cardiovascular patients","volume":"7","author":"James","year":"2005","journal-title":"European Heart Journal Supplements"},{"issue":"5","key":"10.1002\/14651858.CD007654.pub3-BIB62|cit62","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/FJC.0b013e31818713d6","article-title":"Tolerability of sibutramine during a 6-week treatment period in high-risk patients with cardiovascular disease and\/or diabetes: a preliminary analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial","volume":"52","author":"Maggioni","year":"2008","journal-title":"J Cardiovasc Pharmacol"},{"issue":"3","key":"10.1002\/14651858.CD007654.pub3-BIB63|cit63","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1463-1326.2008.00930.x","article-title":"Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT)","volume":"11","author":"Sharma","year":"2009","journal-title":"Diabetes, obesity & metabolism"},{"issue":"9123","key":"10.1002\/14651858.CD007654.pub3-BIB64|cit64","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0140-6736(97)11509-4","article-title":"Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.see comment]","volume":"352","author":"Sjostrom","year":"1998","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD007654.pub3-BIB65|cit65","first-page":"179","article-title":"Comparison of efficacy and safety of rimonabant with orlistat in obese and overweight patients","volume":"2","author":"Suyog","year":"2011","journal-title":"International Journal of Pharma and Bio Sciences"},{"issue":"2","key":"10.1002\/14651858.CD007654.pub3-BIB66|cit66","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/oby.2007.82","article-title":"Effect of orlistat on eating behavior among participants in a 3-year weight maintenance trial","volume":"16","author":"Svendsen","year":"2008","journal-title":"Obesity (Silver Spring)"},{"issue":"3","key":"10.1002\/14651858.CD007654.pub3-BIB67|cit67","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1463-1326.2004.00467.x","article-title":"Effect of orlistat on cardiovascular disease risk in obese adults","volume":"7","author":"Swinburn","year":"2005","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"5","key":"10.1002\/14651858.CD007654.pub3-BIB68|cit68","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1046\/j.1463-1326.2003.00285.x","article-title":"Sibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double-blind, randomized, placebo-controlled trial","volume":"5","author":"Tambascia","year":"2003","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"1","key":"10.1002\/14651858.CD007654.pub3-BIB69|cit69","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/ajcn\/79.1.22","article-title":"Effects of equal weight loss with orlistat and placebo on body fat and serum fatty acid composition and insulin resistance in obese women","volume":"79","author":"Tiikkainen","year":"2004","journal-title":"American Journal of Clinical Nutrition"},{"issue":"3","key":"10.1002\/14651858.CD007654.pub3-BIB70|cit70","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1210\/jc.2011-2486","article-title":"Does rimonabant independently affect free fatty acid and glucose metabolism?","volume":"97","author":"Triay","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"9468","key":"10.1002\/14651858.CD007654.pub3-BIB71|cit71","first-page":"1389","article-title":"Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.see comment]erratum appears in Lancet. 2005 Jul 30-Aug 5;366(9483):370]","volume":"365","author":"Gaal","year":"2005","journal-title":"Lancet"},{"issue":"14","key":"10.1002\/14651858.CD007654.pub3-BIB72|cit72","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1093\/eurheartj\/ehn076","article-title":"Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study","volume":"29","author":"Gaal","year":"2008","journal-title":"European Heart Journal"},{"issue":"11","key":"10.1002\/14651858.CD007654.pub3-BIB73|cit73","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1001\/jama.286.11.1331","article-title":"Long-term weight loss with sibutramine: a randomized controlled trial.see comment]","volume":"286","author":"Wirth","year":"2001","journal-title":"JAMA"},{"issue":"3","key":"10.1002\/14651858.CD007654.pub3-BIB74|cit74","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1067\/mhj.2002.124403","article-title":"Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction","volume":"144","author":"Zannad","year":"2002","journal-title":"American heart journal"},{"issue":"12 Pt 2","key":"10.1002\/14651858.CD007654.pub3-BIB75|cit75","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1097\/00004872-199816121-00024","article-title":"Treatment with orlistat reduces cardiovascular risk in obese patients","volume":"16","author":"Zavoral","year":"1998","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD007654.pub3-BIB76|cit76","unstructured":"Abbott Germany. Theobald F Press release: [Abbott setzt Vertrieb seiner Medikamente mit dem Wirkstoff Sibutramin zur Behandlung von Adipositas in den L\u00e4ndern der Europ\u00e4ischen Union aus.] 2010 Available from: http:\/\/www.abbott.de\/press\/show\/e7340\/e19695\/e18095\/Sibutramin_210110_Theobald_de.pdf"},{"issue":"6","key":"10.1002\/14651858.CD007654.pub3-BIB77|cit77","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1161\/01.HYP.0000165680.59733.d4","article-title":"Effects of weight loss in overweight\/obese individuals and long-term hypertension outcomes: a systematic review","volume":"45","author":"Aucott","year":"2005","journal-title":"Hypertension"},{"issue":"3","key":"10.1002\/14651858.CD007654.pub3-BIB78|cit78","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.cjca.2012.02.018","article-title":"The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy","volume":"28","author":"Daskalopoulou","year":"2012","journal-title":"Can J Cardiol"},{"key":"10.1002\/14651858.CD007654.pub3-BIB79|cit79","unstructured":"The Cochrane Collaboration. Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 Available from: http:\/\/handbook.cochrane.org\/"},{"issue":"9740","key":"10.1002\/14651858.CD007654.pub3-BIB80|cit80","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(10)60935-X","article-title":"Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial","volume":"376","author":"Topol","year":"2010","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD007654.pub3-BIB81|cit81","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1463-1326.2004.00372.x","article-title":"Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients","volume":"7","author":"Derosa","year":"2005","journal-title":"Diabetes, obesity & metabolism"},{"key":"10.1002\/14651858.CD007654.pub3-BIB82|cit82","unstructured":"European Medicines Agency (EMA) Questions and answers on the recommendation to suspend the marketing authorisation of Acomplia (rimonabant) Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Medicine_QA\/2009\/11\/WC500014779.pdf"},{"key":"10.1002\/14651858.CD007654.pub3-BIB83|cit83","unstructured":"European Medicines Agency (EMA) Press Release - The European Medicines Agency recommends suspension of the marketing authorisation of Acomplia Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Press_release\/2009\/11\/WC500014774.pdf"},{"key":"10.1002\/14651858.CD007654.pub3-BIB84|cit84","unstructured":"European Medicines Agency (EMA) Public Statement on\u00a0Acomplia (rimonabant) - Withdrawal of the marketing authorisation in the European Union Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Public_statement\/2009\/11\/WC500012189.pdf"},{"key":"10.1002\/14651858.CD007654.pub3-BIB85|cit85","unstructured":"European Medicines Agency (EMA) Press Release - European Medicines Agency recommends suspension of marketing authorisations for sibutramine Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Press_release\/2010\/01\/WC500069995.pdf 2010"},{"key":"10.1002\/14651858.CD007654.pub3-BIB86|cit86","unstructured":"European Medicines Agency (EMA) Questions and answers on the suspension of medicines containing sibutramine Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Sibutramine_107\/WC500094238.pdf 2010"},{"issue":"6","key":"10.1002\/14651858.CD007654.pub3-BIB87|cit87","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/HJH.0b013e3281fc975a","article-title":"2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"25","author":"Mancia","year":"2007","journal-title":"J Hypertens"},{"key":"10.1002\/14651858.CD007654.pub3-BIB88|cit88","unstructured":"Food Drug Administration. Egan AG Colman EG FDA Rimonabant Briefing Document. Endocrine and Metabolic Drugs Advisory Committee. 2007 Available from: http:\/\/www.fda.gov\/ohrms\/dockets\/AC\/07\/briefing\/2007-4306b1-fda-backgrounder.pdf"},{"key":"10.1002\/14651858.CD007654.pub3-BIB89|cit89","unstructured":"US Food Drug Administration (FDA) Recommendation on a regulatory decision for Meridia (sibutramine) Available from: http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM228795.pdf 2010"},{"key":"10.1002\/14651858.CD007654.pub3-BIB90|cit90","unstructured":"US Food Drug Administration (FDA) FDA News Release: Abbott Laboratories agrees to withdraw its obesity drug Meridia Available from: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/2010\/ucm228812.htm 2010"},{"issue":"6","key":"10.1002\/14651858.CD007654.pub3-BIB91|cit91","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1001\/archinte.168.6.571","article-title":"Long-term effects of weight-reducing interventions in hypertensive patients: systematic review and meta-analysis","volume":"168","author":"Horvath","year":"2008","journal-title":"Archives of internal medicine"},{"key":"10.1002\/14651858.CD007654.pub3-BIB92|cit92","first-page":"19","article-title":"Evaluation of the benefits and harms of non-drug weight-reducing treatment strategies in patients with essential hypertension","volume-title":"Available from: http:\/\/iqwig.de\/download\/A05-21A_Abschlussbericht_Gewichtsreduktion_bei_Bluthochdruck_neu.pdf","author":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen","year":"2006"},{"issue":"19","key":"10.1002\/14651858.CD007654.pub3-BIB93|cit93","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"issue":"9","key":"10.1002\/14651858.CD007654.pub3-BIB94|cit94","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/oby.2003.152","article-title":"Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials","volume":"11","author":"Kim","year":"2003","journal-title":"Obesity Research"},{"key":"10.1002\/14651858.CD007654.pub3-BIB95|cit95","unstructured":"National Institute for Health and Clinical Excellence Hypertension - The clinical management of primary hypertension in adults; Clinical Guideline 127. 2011 Available from: http:\/\/www.nice.org.uk\/nicemedia\/live\/13561\/56007\/56007.pdf"},{"issue":"9555","key":"10.1002\/14651858.CD007654.pub3-BIB96|cit96","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0140-6736(07)60033-6","article-title":"Drug treatments for obesity: orlistat, sibutramine, and rimonabant","volume":"369","author":"Padwal","year":"2007","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD007654.pub3-BIB97|cit97","doi-asserted-by":"crossref","first-page":"264-9, W64","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"issue":"7631","key":"10.1002\/14651858.CD007654.pub3-BIB98|cit98","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1136\/bmj.39385.413113.25","article-title":"Long term pharmacotherapy for obesity and overweight: updated meta-analysis","volume":"335","author":"Rucker","year":"2007","journal-title":"BMJ"},{"issue":"9548","key":"10.1002\/14651858.CD007654.pub3-BIB99|cit99","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/S0140-6736(06)69571-8","article-title":"Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study","volume":"368","author":"Scheen","year":"2006","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD007654.pub3-BIB100|cit100","article-title":"Long-term effects of weight-reducing drugs in hypertensive patients","author":"Siebenhofer","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD007654.pub3-BIB101|cit101","unstructured":"World Health Organization [homepage on the internet]. Khatib OMN El-Guindy MS Clinical guidelines for the management of hypertension. WHO EMRO Technical publication series, 29. 2005 Regional Office for the Eastern Mediterranean. Available from: http:\/\/www.emro.who.int\/dsaf\/dsa234.pdf"},{"key":"10.1002\/14651858.CD007654.pub3-BIB102|cit102","unstructured":"World Health Organization [homepage on the Internet] Fact Sheet 317 - Cardiovascular diseases (CVDs) 2011 Available from: http:\/\/www.who.int\/mediacentre\/factsheets\/fs317\/en\/index.html"}],"updated-by":[{"DOI":"10.1002\/14651858.cd007654.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,3,2]],"date-time":"2016-03-02T00:00:00Z","timestamp":1456876800000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD007654.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T18:59:55Z","timestamp":1688151595000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD007654.pub3"}},"subtitle":[],"editor":[{"given":"Andrea","family":"Siebenhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,3,28]]},"references-count":102,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007654.pub3","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD007654.pub4","asserted-by":"object"}]},"subject":[],"published":{"date-parts":[[2013,3,28]]}}}